Objective To explore the hemodynamics changes of patent foramen ovale (PFO) ofnewborn and early infant.Methods Two groups of cases were analyzed in the study.One group was 60 cases of left-to-right(L-R)shunt in fossa ovalis(FO),the other group was 31 cases of PFO that were foundduring corrective heart surgery but no shunts in FO detected by echocardiography.ACUSON 128 was used.The main indexes were mobility of FO valve,phase,direction,velocity of shunt in FO,jet width.Results ①Valve of FO moved from left to right and right to left with the change of cardiac-period;②44 cages appeared that the jet with<5 mm,Doppler spectrum was two-peaks, positive continuity,peak flow velocity <0.5 m/s;③1 6 cases appeared that the jet width>6 mm,postive wide spectrum,continued from latesystole to diastole,peak flow velocity>0.6 cm/s;④Inside diameter in surgery group was 2～6 mm,meanvalue was 3.4 mm.Conelusions FO valves appears two-directional shunt,the PFO of newborn and early infant mostly appears left-to-right shunt.Atrial septal defect could be diagnosed when the jet width>6 mmand peak flow velocity>0.6 m/s.

Objective: To evaluate the targeting activity in the animal model with human hepatoma, the 131I-human antiHBsAg Fab radioimmunoimaging was explored. Methods: Radioimmunoimagings were taken on different intervals after injection of 131 I-human anti-HBsAg Fab to the nude mice and tissue distribution was measured. The human anti-HBsAg Fab was compared with the murine monoclonal antibodies. Results: The experimental group developed tumor positive images after 3 days of radio-labeled monoclonal antibodies injection, and the peak accumulation of radio-activity on the 5th day.Statistics indicated the tumor/liver ratio of the human anti-HBsAg Fab, murine monoclonal antibodies and the control groups were 5.4,4.0 and 0.9 respectively on the 7th day. Conclusions: Our results suggest that the 131 I-human anti-HB-sAg Fab has a considerable targeting activity, and provide an evidence that it can be used as a novel humanized carrer for targeting therapy of hepatoma.